Post-Market & Real-World Study Service

Overview

The transition from highly controlled randomized controlled trials (RCTs) to the wild of clinical practice is the most critical phase in a drug's life cycle. While RCTs establish efficacy, only post-market & real-world study services can confirm a therapy's long-term safety, effectiveness, and economic value in diverse, unconstrained patient populations. Protheragen leverages high-fidelity real-world data (RWD) to generate robust real-world evidence (RWE). Our services help sponsors navigate the complexities of post-marketing surveillance, support market access negotiations, and unlock new therapeutic insights that are often invisible within the narrow parameters of traditional clinical research.

Evidence Beyond the Trial, Mastering the Real-World Landscape - Strategic RWE for Obesity Therapeutics

Protheragen provides the analytical bridge between clinical discovery and commercial sustainability. We specialize in designing pragmatic clinical trials and observational studies that capture the nuances of metabolic health in the real world.

Long-term Efficacy & Safety Validation

We track the performance of anti-obesity medications over the years, identifying rare adverse drug events (ADEs) and evaluating the durability of weight loss in patients with multiple comorbidities. This data is critical for updating the Safety Monitoring & Signal Management Service profile and ensuring that the drug's risk management plan (RMP) remains accurate. To support this, we offer:

Precision Real-World Monitoring

By integrating diverse data sources, including information from wearables and mobile health (mHealth) applications through our Database Construction & Data Management Service, we capture high-frequency data on patients' physical activity levels and dietary adherence. This comprehensive approach allows us to provide a multidimensional view of patient progress over time, revealing patterns that may not be visible with conventional monitoring methods. By analyzing these continuous insights, we empower clinicians to tailor interventions more effectively, ultimately driving better health outcomes and enhancing the management of obesity and related comorbidities in diverse patient populations.

Advanced Population Analytics

We conduct a thorough analysis of how various factors, such as genetics, lifestyle, and social determinants of health, influence the response to obesity therapies in real-world settings. By integrating multi-omics data, behavioral metrics, and environmental variables, we equip clinicians with the knowledge needed to identify the most appropriate patients for specific therapies. This tailored approach ensures that treatment plans are not only effective but also personalized, taking into account the unique characteristics and circumstances of each patient.

Workflow

Protheragen employs a rigorous, evidence-centric workflow designed to transform disparate RWD into a high-fidelity evidence base. Our methodology emphasizes ecological validity and regulatory alignment, ensuring that observations from clinical practice are translated into structured insights that meet the standards of both payers and regulators. By synchronizing data collection from EHRs, insurance claims, and patient registries, we provide a holistic view of the drug's performance that supports long-term life-cycle management.

Submit Your Clinical Protocol for a Comprehensive Readiness Evaluation Session.

Applications

• Payer & Reimbursement Strategy

Generating economic evidence to prove that an anti-obesity drug reduces the long-term cost of comorbidities (e.g., type 2 diabetes, cardiovascular disease), facilitating inclusion in national formularies and private insurance coverage.

• Device Performance Monitoring

Conducting post-market surveillance for obesity-related medical devices (e.g., gastric balloons or electrical stimulators). This supports the identification of long-term risks and confirms the device's utility in non-specialized clinical settings.

• Body Composition & Precision Health

Utilizing RWD to assess how new incretin-based therapies affect body composition (muscle mass vs. fat mass) over time. This provides clinicians with more granular data than simple BMI changes, supporting the obesity prediction service.

• Indication Expansion & Lifecycle Support

Providing the safety and efficacy evidence needed to support a BLA/NDA for new patient groups (e.g., pediatric patients or those with specific metabolic syndrome profiles) without requiring a full new RCT.

Advantages

Comprehensive Clinical Research Solutions

Protheragen offers a comprehensive integrated service framework designed to ensure that your therapy delivers ongoing value well beyond its initial approval. Our post-market services are meticulously crafted to feed back into our discovery and clinical platforms, fostering a continuous loop of metabolic intelligence. This dynamic system not only aids in the timely identification of new therapeutic insights but also supports adaptive strategies for product optimization, ultimately enhancing patient outcomes and maintaining the relevance of your treatment in a rapidly evolving healthcare landscape.

Publication Data

Schedule a Specialized Consultation to Access Integrated Regulatory Intelligence Solutions.

Customer Review

Frequently Asked Questions

1. What is the difference between RWD and RWE?

   RWD refers to the raw information collected from sources like EHRs, claims, and registries. RWE is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of that RWD.

2. How does Protheragen ensure the quality and regulatory acceptability of real-world data?

   We implement a rigorous data validation framework that includes source data verification, automated quality checks, and compliance with FDA/EMA RWE guidance. Our protocols ensure that data from EHRs, claims, and registries meet the standards required for regulatory submissions and payer negotiations.

3. Can RWE be used to support a new drug application?

   Yes. The FDA and EMA increasingly accept high-quality RWE to support safety and efficacy claims, particularly for label expansions, orphan drugs, or as a historical control in specific trial designs.

Protheragen is dedicated to ensuring that your therapeutic breakthroughs stand the test of time and the scrutiny of the real world. Whether you are exploring new market opportunities or enhancing your overall strategy, our RWE experts are here to guide you. Contact us today to discuss a customized real-world study for your obesity program.